3 news published.
In today's market highlights, Dr. Reddy's Laboratories (RDY) unveiled robust financial results for Q1FY25, showcasing a revenue increase of 14% YoY to ₹76,727 million. This growth reflects a strong performance in its Global Generics segment, particularly in North America and India. Key metrics from the report included:
- Gross Margin: improved to 60.4%
- EBITDA: ₹21,599 million (28.2% of revenues)
- Profit after Tax: ₹13,920 million (down 1% YoY, up 7% QoQ)
Additionally, Dr. Reddy’s continues to invest strategically in areas such as biologics and consumer healthcare, highlighted by their recent acquisition of Nicotinell® brands and partnerships with industry leaders like Novartis and Alvotech for product commercialization. Read More
Don't miss out on market-moving news. Bookmark this page and check back regularly for the most recent updates on stocks, sectors, and the overall market landscape. Stay informed, stay ahead, and make smarter investment choices with our comprehensive stock news coverage.
Stay ahead of the market with our list of today's most important stock news and financial updates. Whether you're a day trader, long-term investor, or market enthusiast, our news feed covers everything you need to know about publicly traded companies.
Our news feed is designed for investors who want to stay informed about the latest developments affecting their portfolio or watchlist. Whether you're researching potential investments, monitoring your current holdings, or simply staying up-to-date with market trends, our stock news page provides the information you need to make informed decisions.
